Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)

BACKGROUND: Traditionally believed to be an integral part of multiple myeloma (MM) treatment, the role of hematopoietic stem-cell transplantation (HSCT) is being challenged. As such, we sought to evaluate the impact of HSCT in the era of novel agents. METHODS: A multicenter, retrospective, longitudi...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Ja Min, Yoon, Sung-Soo, Koh, Youngil, Min, Chang-Ki, Lee, Jae Hoon, Jo, Jaemin, Park, Hyunkyung, Lee, Jiyun, Kang, Ka-Won, Lee, Yoojin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Advances in Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236395/
https://www.ncbi.nlm.nih.gov/pubmed/32523660
http://dx.doi.org/10.1177/2040620720921046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236395/
https://www.ncbi.nlm.nih.gov/pubmed/32523660
http://dx.doi.org/10.1177/2040620720921046

Ejemplares similares